Lida Holdings Ltd. 4552

JCR Pharmaceuticals (TSE:4552) saw losses deepen at an annual rate of 40% over the past five years, with no improvement in net profit margin during that stretch. Revenue is expected to decline at 0.5% per year for the next three years, even as forecasts point to earnings growth averaging 34.82% annually. With profitability anticipated within the next three years, the company sets up as a potential turnaround story amid a challenging backdrop for margins and growth. See our full analysis for...